ArticleUpdates in surgery2026
Single-port versus multi-port robotic complete mesocolic excision for right colon cancer.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Minimally invasive approaches have transformed right cancer surgery, with robotic platforms enhancing challenging techniques like complete mesocolic excision (CME). While traditionally performed using the da Vinci® Multiport system (MP), the introduction of the Single Port™ platform (SP) offers a valuable alternative. This study aims to evaluate the technical feasibility and pathologic surrogates of resection adequacy of robotic right colectomy with CME performed with the daVinci SP® compared to the daVinci Xi® platform in selected patients. From February 2024 to February 2025 consecutive patients who underwent robotic right colectomy and CME either with MP or SP platform were enrolled in the study. The two populations of patients were compared with particular attention to number and location of lymph nodes harvested as a surrogate outcome for oncologic adequacy. From February 2024 to February 2025, 52 consecutive patients were enrolled in the study. There were no differences in population characteristics with the exception for BMI, which was lower in the SP group. Operative times were longer in the SP group. No differences were noticed in either postoperative outcomes such as length of stay (LOS) or complications rate nor in pathological findings, especially in the number of apical lymph node harvested. SP robotic right colectomy with CME appears feasible and achieves pathologic surrogates of resection adequacy comparable to MP surgery in highly selected patients.
Indexed as
Identifiers
42920087What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.